Protara Therapeutics, Inc. (TARA)

US — Healthcare Sector
Peers: VCNX  MNPR  MIRO  SRZN    IKNA  XLO  SRRK  VACC  MTCR  MGTA  TCON  STSA  LYRA  TRVI  SQZ 

Automate Your Wheel Strategy on TARA

With Tiblio's Option Bot, you can configure your own wheel strategy including TARA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TARA
  • Rev/Share 0.0
  • Book/Share 3.8932
  • PB 0.786
  • Debt/Equity 0.0267
  • CurrentRatio 18.0296
  • ROIC -0.3161

 

  • MktCap 118060614.0
  • FreeCF/Share -0.9887
  • PFCF -2.9333
  • PE -2.7428
  • Debt/Assets 0.0251
  • DivYield 0
  • ROE -0.3637

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation TARA Scotiabank -- Sector Outperform -- $12 April 16, 2025
Initiation TARA Cantor Fitzgerald -- Overweight -- -- March 14, 2025

News

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
TARA
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ, or CIS (± Ta/T1), who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve. The results will be featured today during an interactive poster session at the American Urological Association 2025 Annual Meeting in Las Vegas.

Read More
image for news Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
TARA
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Protara Therapeutics (TARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
TARA
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 9:50 am ET in Boston. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com.

Read More
image for news Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

About Protara Therapeutics, Inc. (TARA)

  • IPO Date 2014-10-22
  • Website https://www.protaratx.com
  • Industry Biotechnology
  • CEO Mr. Jesse Shefferman
  • Employees 28

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.